Affiliation:
1. From the Hospital Universitario 12 de Octubre; Hospital Universitario Ramón y Cajal; Clínico San Carlos; and Hospital Universitario de la Princesa, Madrid; Hospital Universitario de Salamanca, Centro de Investigación del Cáncer–Instituto de Biolia Molecula y Celular del Cancer de Salamanca (Universidad de Salemanca-Centros Superior de Investigaciones Aèntîficas) Salamanca; Hospital Clinic, Institut d’Investigacions Biomédiques August Pi I Sunyer; Hospital de la Santa Creu i Sant Pau, Barcelona; Hospital...
Abstract
Purpose Complete response (CR) is considered an important goal in most hematologic malignancies. However, in multiple myeloma (MM), there is no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial response (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM. Patients and Methods We analyzed 632 patients from the prospective Grupo Español de Mieloma 2000 protocol who were uniformly treated with vincristine, carmustine, cyclophosphamide, melphalan, and predisone/vincristine, carmustine, adryamcine, and dexamethasone induction followed by high-dose therapy and autologous stem-cell transplantation. Results Post-transplantation response markedly influenced outcomes. Patients achieving CR had significantly longer EFS (median, 61 v 40 months; P < 10−5) and OS (medians not reached; P = .01) versus patients achieving nCR, who likewise had somewhat better outcomes compared with patients achieving PR (median EFS, 34 months, P = .07 v nCR; median OS, 61 months, P = .04). EFS and OS and influence of response were similar among older (age 65 to 70 years) and younger (age < 65 years) patients. Similar findings were observed with pretransplantation response, with trends toward EFS (P = .1; P = .05) and OS (P = .1; P = .07) benefit in patients achieving CR versus nCR and PR, respectively. Post-transplantation response was markedly influenced by pretransplantation response; improvements in response were associated with prolonged survival. Conclusion Quality of response post-transplantation, notably CR, is significantly associated with EFS and OS prolongation in newly diagnosed patients with MM. There were trends toward similar associations with pretransplantation response status.
Publisher
American Society of Clinical Oncology (ASCO)
Reference49 articles.
1. Corso A, Nozza A, Lazzarino M, et al: Plateau phase in multiple myeloma: An end-point of conventional-dose chemotherapy. Haematologica 84:336,1999-341,
2. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
3. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
4. Gore ME, Selby PJ, Viner C, et al: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2:879,1989-882,
5. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma
Cited by
258 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献